Excellent data. Now I have a clear picture of fresh US insider activity. Let me write the article.
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish
Excellent data. Now I have a clear picture of fresh US insider activity. Let me write the article.
Insiders Sell Big, One CEO Bets Bold
Insider filings hit the tape this week with a mix of notable exits and a standout buy that stands apart from the crowd.
KO CEO James Quincey filed on May 11, disclosing he sold $15.8 million worth of Coca-Cola shares on May 7. The 200,000-share sale is one of the largest C-suite disposals filed this week.
DVA CFO Joel Ackerman also sold, offloading $9.9 million in DaVita stock on May 7. The filing landed May 11. Both sales came days after a broad market rally — a telling choice of timing.
DOCN saw a flood of sell orders. Access Industries Holdings, a 10% owner, filed multiple block sales totalling over $29 million across May 7 and 11. That level of concentration from a single holder is hard to ignore.
On the buy side, WGS stands out. Corvex Management, a board-linked fund at GeneDx Holdings, filed purchases of nearly $19.7 million on May 11 alone — snapping up roughly 499,000 shares at around $39. That is a high-conviction move into a genomics company with a short interest worth watching.
TXO Partners Founder and Chairman Bob Simpson also bought $6.3 million in TXO on May 11. Founders buying their own stock at scale is always worth flagging.
Veeco Instruments CEO William Miller sold $5.96 million in VECO stock, and CVS CTO Tilak Mandadi exited $6.2 million in CVS shares the same week.
This article is for informational purposes only and does not constitute financial advice.
How this article was generated
- Generated
- 13 May 2026, 08:11
- Prompt version
- migrated
- Data sources
- Institutional positioningAlt DataIndex Rebalance
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.